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A 52 year old, never smoker presented to hospital with progressive shortness of breath and signiﬁcant
stridor over a ﬁve month period. He also described the feeling of needing to cough but being unable to
expectorate. CT Thorax demonstrated a mass lesion in the trachea just distal to the larynx which was
then conﬁrmed on rigid bronchoscopy. Subsequent histology conﬁrmed an epithelial-myoepithelial
carcinoma.
Only a few case reports document these rare salivary gland tumours occurring in other locations such
as the respiratory tract. After staging showed only local disease, the patient was managed with rigid
bronchoscopy and laser ablation therapy.
We present the ﬁrst documented case to be treated with endobronchial laser ablation therapy with
discussion of the incidence, presentation and characteristics of these tumours including the treatment
options, as well as the use of laser ablation in the management of benign and malignant endobronchial
lesions.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Epithelial-myoepithelial carcinoma is a rare, apparently low
grade malignancy of the salivary glands which occurs most
commonly in the parotid gland. These tumours may also present in
other manners such as primary pulmonary malignancies with only
a very small number of cases previously reported.
Of these pulmonary manifestations, the frequent presentations
include breathlessness, cough, occasional haemoptysis or often
even as incidental ﬁndings, with only one case documenting stridor
as a key feature, as in our case.
Due to the extremely infrequent presentation of such cases, no
deﬁned treatment paradigms or “gold standards” exist. We present
the ﬁrst documented case to be treated with endobronchial laser
ablation therapy.
2. Case presentation
A 52 year old, previously ﬁt and well gentleman presented to
hospital with progressive shortness of breath and signiﬁcant stridorracken).
Ltd. This is an open access article uover a ﬁve month period. He also described the feeling of needing
to cough but being unable to expectorate. He gave no history of
haemoptysis or weight loss.
He was a never smoker who gave no personal or contact history
of tuberculosis, no signiﬁcant occupational exposures and no his-
tory of asthma or atopy, although his GP had treated his progressive
dyspnoea as asthma with inhaled bronchodilators to no effect. He
had no other signiﬁcant past medical history or drug history.
Computed Tomography (CT) of the Thorax (Fig. 1) demonstrated
a twelve millimetre, partially obstructive, pedunculated mass
lesion in the trachea just distal to the larynx at the level of C7 which
was then conﬁrmed on rigid bronchoscopy. A staging CT showed no
metastatic disease or lymphadenopathy.
Biopsy specimens obtained following laser ablation were
initially non-diagnostic but were felt to represent low grade
tumour derived from an accessory gland in the mucosa. Specialist
expert input was sought from pathologists in the Royal Brompton
Hospital, London. Their report described ﬁbrovascular stroma
inﬁltrated by an epithelial tumour comprising of solid islands and
tubular aggregates of mild to focally moderately pleomorphic
epithelial cells. The epithelial cells showed irregular inﬁltration. In
areas of tubular architecture, a focal dual layer was noted, with the
inner layer staining for cytokeratines and the outer layer stainingnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Axial CT image demonstrating partially occlusive, pedunculated tracheal lesion.
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moderate non-speciﬁc chronic inﬂammatory cell inﬁltrate.
Given the morphology, the specimens were classiﬁed as an
epithelial-myoepithelial carcinoma.
Management options were discussed at the regional lung cancer
multidisciplinary team meeting involving respiratory, thoracic and
oncology specialist teams and the decision was made to proceed
with rigid bronchoscopy and laser ablation therapy.
A Nd-YAG laser was used with the ﬁbre passed through a
ﬁbreoptic bronchoscope which was then passed through a rigid
bronchoscope, the latter being required to control the airway. Initial
biopsies were fragmented meaning that margins could not be
adequately assessed and so further laser ablation therapy was un-
dertaken in an attempt to ensure satisfactory removal of the entire
lesion.
Positron Emission Tomography (PET-CT) demonstrated no
abnormal active uptake at the original site of the lesion, or at any
distant metastatic or nodal site, and the decision was made for
follow up with surveillance CT and bronchoscopy initially after 3
months.
3. Discussion
Tracheal tumours are extremely rare and have been estimated to
comprise approximately 0.1% of all malignancies [1] with ﬁgures for
new cases quoted between 1.4 and 2.6 per 1,000,000 every year
[2,3].
Of these cases of tracheal tumours, the majority are made up of
squamous cell carcinoma and adenoid cystic carcinoma, but sali-
vary gland tumours may also occur infrequently due to the pres-
ence of submucosal glands in the trachea and bronchi [4].
Epithelial-myoepithelial tumours are low grade, indolent ma-
lignancies of the salivary glands, most commonly the parotids, with
only approximately 120 documented cases [5], thus representing
approximately 1% of salivary gland tumours [6]. They may also
seldom occur in extraglandular locations such as the respiratory
tract, a location which comprises a tenth of the number of cases
documented [4].
Histologically these are malignant tumours composed of two
cell types in varying proportions creating a double layer. These
consist of an inner layer of eosinophilic, duct lining epithelial cells
creating a tubular structure, surrounded by an outer layer of solid,
clear myoepithelial cells [7].
Treatment options for these cases remains unclear. The
consensus has been that wide surgical excision, in keeping with the
routine management of salivary gland tumours, may be appro-
priate, and the majority of case studies have demonstrated this in
the form of segmental tracheal resection with end-to-end anasto-
mosis [5,7]. The necessity for negative margins from surgical
resection is generally accepted as a minimum [9] as incompleteexcision is associated with local recurrence and metastases [6]. It
has been suggested that recurrence rates may be as high as 40% but
this may be, at least in part, due to incomplete resection [6]. Very
little evidence exists as to the beneﬁt of radiotherapy or chemo-
therapy; however one case report describes complete resolution of
metastatic disease with chemotherapy [8].
Endobronchial laser ablation therapy is a treatment option for
patients with benign and malignant tracheal or bronchial tumours
with its evidence base strongly established in the 1980s and 90s
[10e12].
In the past, it has more commonly been used in benign lesions
or in those patients for whom treatment is not intended to be
curative. This is due to the advanced stage of disease often evident
at presentation and the invasive and aggressive nature of many
primary lung malignancies. In these cases, laser ablation is used to
give symptomatic relief by debulking tumour and removing the
endobronchial obstruction [13].
Increasingly, however, laser ablation is being used in patients
with early malignancy or low-grade malignancy. Many screening
programmes, along with the improvement of imaging and staging
techniques have resulted in an increase in stage I and II cancers
detected, allowing for less invasive treatment strategies. Endo-
bronchial laser ablation can be seen as a suitable, curative, non-
invasive management option when staging investigations have
demonstrated minimal invasion and no nodal involvement or
metastases, with some studies demonstrating 90e100% success
rates with regards to recurrence at 5 years [13e15].
In this case, the multidisciplinary team felt that endobronchial
laser ablation was an appropriate treatment option given the low
grade nature of the lesion, no evidence of local invasion, no nodal
involvement or metastases, but also given the reduced procedural
morbidity andmortality, and the cost effectivenesswhen compared
with other surgical options such as segmental tracheal resection
with anastomosis.
Due to the signiﬁcant recurrence rates quoted for epithelial-
myoepithelial carcinoma, early follow up at three months with
repeat computed tomography and bronchoscopy have been
arranged.
4. Conclusions
 Tracheal tumours are extremely rare but salivary gland tumours
may occasionally present in the respiratory tract due to the
presence of submucosal glands
 Epithelial-myoepithelial tumours are low grade malignancies of
the salivary glands that seldom occur in extraglandular locations
 Treatment options are unclear due to the small number of cases
but surgical resection with negative margins is generally
considered a minimum
 Endobronchial laser ablation therapy has an increasing role in
the curative management of malignant lesions with minimal
invasion and no nodal involvement or metastases
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